The therapeutic cancer vaccines market is anticipated to grow rapidly throughout the forecast period from an estimated $0.59 billion in 2013 to approximately $7.59 billion by 2019, driven primarily by the approval of up to 12 vaccines across seven indications, six of which have no currently approved therapeutic vaccine.
The US is predicted to be the largest market due to the anticipated higher performance of these novel vaccines within this market where, unlike in the European markets, sales will not be severely restricted by their high cost-to-clinical-benefit ratio. The US market will also be driven by the high cost of the vaccines as specialty drugs, which is set to increase yearly at a rate substantially higher than that of the consumer price index.
As such, the US market is predicted to account for 96% of the total global therapeutic cancer vaccines market in 2013, decreasing slightly to 94% in 2019 with the approval of numerous vaccines in the EU and Japan, but remaining overwhelmingly dominant throughout the forecast period and into the foreseeable future.
Buy now and…
Understand the variation in the types of therapeutic cancer vaccines, and the strength and weaknesses of each form..
Understand the vast scope of the pipeline, including which vaccine types and molecular targets are generating the most interest.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the therapeutic cancer vaccines market..